The firm rates MJardin as a 'Hold' and Tilt Holdings as a 'Speculative Buy.'
Let's visit with the charts and indicators to see how things are shaping up today.
Besides revisiting the first two companies, we also look at trade setups for Canopy Growth and Nike.
With over 56 brands, CRLBF has something for everyone and that is the secret sauce of this unassuming company.
The market for hemp-derived products is exploding and financial instruments that are going to be created to work within the market will grow, too.
I believe the best move here is to cut the position in half and take a loss.
Sales for Pot Holiday 420 will get rolling early this year. Any cannabis investor should pay attention.
CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.
For aggressive investors seeking to broaden their exposure in the cannabis and CBD space, I view VFF as an opportunity.
The company has spent a lot of time and money trying to meet the supply needs of the recreational cannabis market.
A pair of earnings report this week will shed light on the future direction of two fast-growing companies in very different fields.
Five top marijuana stocks and four CBD plays in this speculative space.
Oh, by the way, Constellation, for those who've forgotten, holds a 38% stake in Canopy Growth.
There is certainly too much to ignore about STZ for the majority of analysts.
The cannabis company said it was going to invest in its own delivery service called "Chill."
In fact, the de-emphasizing of cigarettes was blamed for declining same store sales.
Is Walgreens now a cannabis value play?
This legal-marijuana company is flying under the radar after a scandal involving two ex-employees.
Charts of this type are frequently found to be topping patterns.
Revenue is where it's at for cannabis in 2019.
A huge week is coming up for these well-known stocks.
Investors can gain exposure to the high-flying cannabis industry without taking on undue risks.
If Plus cannabis gummies are a big hit, just think how consumers will respond to hemp-derived CBD gummies.
It might not be time to panic yet about Tilray, but there's likely a problem ahead.
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Investors looking for another hemp play might consider Charlotte's Web Holdings, which deals in a range of CBD wellness products.
A key aspect of the international expansion is the company's recent acquisition of hemp-food producer Manitoba Harvest in February.
Apparently, this game is all about growth right now. It certainly is not about margins.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Let's check out the charts and indicators for this so-called pot play.